WASHINGTON — In a closed-door meeting Thursday morning, Sen. Mitt Romney (R-Utah) warned the trade group for the United States’ largest drug companies that he and his new colleagues are working to address high prescription drug prices — and that the industry should participate in those discussions.

“My view was that there is going to be change with regards to pharmaceutical pricing and that I think they would be wise to try and shape the reforms as opposed to hoping nothing will happen, because I think some change is coming,” Romney told STAT in a brief interview this afternoon, when asked about his message to the board of directors for PhRMA, the trade association that represents companies like Amgen, Gilead, and Eli Lilly.